Systematic Analysis of Gene Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma with a Case Study of FAM83A and FAM83B

被引:14
|
作者
Cai, Ling [1 ,2 ,3 ]
Luo, Danni [1 ]
Yao, Bo [1 ]
Yang, Donghan M. [1 ]
Lin, Shin Yi [1 ]
Girard, Luc [4 ]
DeBerardinis, Ralph J. [2 ,3 ]
Minna, John D. [4 ]
Xie, Yang [1 ]
Xiao, Guanghua [1 ]
机构
[1] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Dept Populat & Data Sci, Quantitat Biomed Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
[2] UT Southwestern Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA
[3] UT Southwestern Med Ctr, Childrens Med Ctr Res Inst, Dallas, TX 75390 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dept Internal Med, Hamon Ctr Therapeut Oncol Res,Dept Pharmacol, Dallas, TX 75390 USA
来源
CANCERS | 2019年 / 11卷 / 06期
关键词
lung cancer; gene expression difference between tumor and normal; survival association analysis; systematic analysis; meta-analysis; FAM83; CLASS-II EXPRESSION; CANCER; SURVIVAL; EGFR;
D O I
10.3390/cancers11060886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: In our previous study, we constructed a Lung Cancer Explorer (LCE) database housing lung cancer-specific expression data and clinical data from over 6700 patients in 56 studies. Methods: Using this dataset of the largest collection of lung cancer gene expression along with our meta-analysis method, we systematically interrogated the association between gene expression and overall survival as well as the expression difference between tumor and normal (adjacent non-malignant tissue) samples in lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SQCC). A case study for FAM83A and FAM83B was performed as a demonstration for hypothesis testing with our database. Results: We showed that the reproducibility of results across studies varied by histological subtype and analysis type. Genes and pathways unique or common to the two histological subtypes were identified and the results were integrated into LCE to facilitate user exploration. In our case study, we verified the findings from a previous study on FAM83A and FAM83B in non-small cell lung cancer. Conclusions: This study used gene expression data from a large cohort of patients to explore the molecular differences between lung ADC and SQCC.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators
    Grant, Steven
    JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (09): : 3048 - 3051
  • [2] FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
    Richtmann, S.
    Wilkens, D.
    Warth, A.
    Lasitschka, F.
    Winter, H.
    Christopoulos, P.
    Herth, F.
    Muley, T.
    Meister, M.
    Schneider, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S964 - S964
  • [3] FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
    Richtmann, Sarah
    Wilkens, Dennis
    Warth, Arne
    Lasitschka, Felix
    Winter, Hauke
    Christopoulos, Petros
    Herth, Felix J. F.
    Muley, Thomas
    Meister, Michael
    Schneider, Marc A.
    CANCERS, 2019, 11 (05)
  • [4] FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma
    Okabe, Naoyuki
    Ezaki, Junji
    Yamaura, Takumi
    Muto, Satoshi
    Osugi, Jun
    Tamura, Hirosumi
    Imai, Jun-Ichi
    Ito, Emi
    Yanagisawa, Yuka
    Honma, Reiko
    Gotoh, Mitsukazu
    Watanabe, Shinya
    Waguri, Satoshi
    Suzuki, Hiroyuki
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (03) : 999 - 1006
  • [5] FAM83B, A NOVEL MOLECULAR TARGET FOR LUNG SQUAMOUS CELL CARCINOMA.
    Okabe, Naoyuki
    Suzuki, Hiroyuki
    Higuchi, Mitsunori
    Osugi, Jun
    Hasegawa, Takeo
    Yaginuma, Hiroshi
    Muto, Satoshi
    Yamaura, Takumi
    Watanabe, Yuzuru
    Owada, Yuki
    Watanabe, Shinya
    Waguri, Satoshi
    Ezaki, Jyunji
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S484 - S485
  • [6] FAM83A and FAM83A-AS1 both play oncogenic roles in lung adenocarcinoma
    Wang, Gaoming
    Li, Xiaokun
    Yao, Yu
    Jiang, Zhisheng
    Zhou, Hai
    Xie, Kai
    Luo, Jing
    Shen, Yi
    ONCOLOGY LETTERS, 2021, 21 (04)
  • [7] Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma
    Zhang, Junqiang
    Sun, Gengyun
    Mei, Xiaodong
    CANCER BIOMARKERS, 2019, 26 (03) : 367 - 373
  • [8] Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma
    Liu, Xin
    Fu, Meng
    Xia, Daqing
    Ji, Zimei
    Hu, Nana
    Leng, Zaijun
    Xie, Wang
    Fang, Yuan
    Zhang, Junqiang
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [9] FAM83A Is a Prognosis Signature and Potential Oncogene of Lung Adenocarcinoma
    Yu, Jing
    Hou, Min
    Pei, Tianxian
    DNA AND CELL BIOLOGY, 2020, 39 (05) : 890 - 899
  • [10] LncRNA FAM83A-AS1 promotes lung adenocarcinoma progression by enhancing the pre-mRNA stability of FAM83A
    Wang, Wenyi
    Zhao, Zhunlin
    Xu, Chun
    Li, Chang
    Ding, Cheng
    Chen, Jun
    Chen, Tengfei
    Zhao, Jun
    THORACIC CANCER, 2021, 12 (10) : 1495 - 1502